{"id":"covid19-convalescent-plasma-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Transfusion-associated circulatory overload (TACO)"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL4650372","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The infusion contains polyclonal antibodies and other immune components from donors who have recovered from COVID-19, which neutralize the virus and enhance immune clearance in infected recipients. This passive immunotherapy approach aims to reduce viral load, prevent disease progression, and improve clinical outcomes in hospitalized COVID-19 patients, particularly those with severe disease or immunocompromised status.","oneSentence":"COVID-19 convalescent plasma infusion transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against SARS-CoV-2.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:49.424Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (severe or life-threatening disease)"},{"name":"COVID-19 (hospitalized patients)"}]},"trialDetails":[{"nctId":"NCT04497779","phase":"","title":"Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-07-13","conditions":"Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":95},{"nctId":"NCT04803370","phase":"NA","title":"Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma","status":"COMPLETED","sponsor":"Hospital Son Llatzer","startDate":"2020-07-08","conditions":"Covid19","enrollment":55},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04390503","phase":"PHASE2","title":"Convalescent Plasma for Early Treatment of COVID-19","status":"TERMINATED","sponsor":"Andrew Eisenberger","startDate":"2021-03-12","conditions":"SARS-CoV 2, COVID-19","enrollment":223},{"nctId":"NCT04973488","phase":"NA","title":"Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"Novacescu Alexandru","startDate":"2020-07-25","conditions":"COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure","enrollment":38},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT04354831","phase":"PHASE2","title":"Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2020-05-11","conditions":"COVID-19","enrollment":131},{"nctId":"NCT04377672","phase":"PHASE1","title":"Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-05-28","conditions":"SARS-CoV-2 Infection","enrollment":14},{"nctId":"NCT04340050","phase":"EARLY_PHASE1","title":"COVID-19 Convalescent Plasma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-04-10","conditions":"Coronavirus","enrollment":10},{"nctId":"NCT04355897","phase":"EARLY_PHASE1","title":"CoVID-19 Plasma in Treatment of COVID-19 Patients","status":"COMPLETED","sponsor":"The Christ Hospital","startDate":"2020-04-28","conditions":"COVID 19","enrollment":22},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04420988","phase":"","title":"Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Rutgers, The State University of New Jersey","startDate":"","conditions":"COVID-19, SARS-CoV 2, SARS-CoV Infection","enrollment":""},{"nctId":"NCT04456413","phase":"PHASE2","title":"Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2020-11-06","conditions":"COVID-19","enrollment":21},{"nctId":"NCT04343755","phase":"PHASE2","title":"Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2020-04-09","conditions":"COVID-19","enrollment":52},{"nctId":"NCT04433910","phase":"PHASE2","title":"A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19","status":"COMPLETED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2020-08-30","conditions":"COVID-19","enrollment":106},{"nctId":"NCT04445207","phase":"","title":"Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Jonathan Gerber","startDate":"","conditions":"COVID, Sars-CoV2, Corona Virus Infection","enrollment":""},{"nctId":"NCT04891172","phase":"PHASE2, PHASE3","title":"Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2021-08-01","conditions":"Covid19","enrollment":310},{"nctId":"NCT04472572","phase":"","title":"Expanded Access to Convalescent Plasma for Treatment of COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Hackensack Meridian Health","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04421404","phase":"PHASE2","title":"Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients","status":"COMPLETED","sponsor":"Priscilla Hsue, MD","startDate":"2020-06-09","conditions":"COVID-19, Sars-CoV2","enrollment":34},{"nctId":"NCT04382651","phase":"PHASE2","title":"Study of Efficacy and Safety of MAS825 in Patients With COVID-19","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-11","conditions":"COVID-19 Pneumonia, Impaired Respiratory Function","enrollment":140},{"nctId":"NCT04345289","phase":"PHASE3","title":"Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia","status":"TERMINATED","sponsor":"Thomas Benfield","startDate":"2020-05-01","conditions":"COVID, Corona Virus Infection, Viral Pneumonia","enrollment":147},{"nctId":"NCT04535063","phase":"PHASE3","title":"Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","startDate":"2020-04-18","conditions":"Covid19 Pneumonia","enrollment":200},{"nctId":"NCT04415086","phase":"PHASE2","title":"Treatment of Patients With COVID-19 With Convalescent Plasma","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-06-01","conditions":"COVID-19","enrollment":129},{"nctId":"NCT04374565","phase":"PHASE2","title":"Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-05-05","conditions":"Corona Virus Infection, SARS-CoV 2, SARS Pneumonia","enrollment":29},{"nctId":"NCT04589949","phase":"PHASE3","title":"Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2020-10-12","conditions":"Covid19","enrollment":420},{"nctId":"NCT04342182","phase":"PHASE2, PHASE3","title":"Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2020-04-08","conditions":"COVID-19","enrollment":86},{"nctId":"NCT05247307","phase":"PHASE3","title":"Efficacy of the Infusion of Donor Plasma in COVID-19 Infection","status":"TERMINATED","sponsor":"Hospital Galdakao-Usansolo","startDate":"2020-03-31","conditions":"COVID-19","enrollment":93},{"nctId":"NCT04348656","phase":"PHASE3","title":"CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","status":"TERMINATED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2020-03-14","conditions":"COVID-19","enrollment":940},{"nctId":"NCT04649879","phase":"PHASE2, PHASE3","title":"Convalescent Plasma for Treatment of COVID-19","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-12-03","conditions":"Covid19","enrollment":59},{"nctId":"NCT05200754","phase":"PHASE2","title":"Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19","status":"UNKNOWN","sponsor":"Carsten Müller-Tidow","startDate":"2020-09-03","conditions":"SARS-CoV-2 Infection","enrollment":174},{"nctId":"NCT04502472","phase":"PHASE2, PHASE3","title":"Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2020-06-06","conditions":"Covid-19","enrollment":109},{"nctId":"NCT04390178","phase":"PHASE1, PHASE2","title":"Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-04-10","conditions":"COVID-19","enrollment":10},{"nctId":"NCT04384497","phase":"PHASE1, PHASE2","title":"Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-05-07","conditions":"COVID-19","enrollment":10},{"nctId":"NCT04458363","phase":"EARLY_PHASE1","title":"Convalescent Plasma in Pediatric COVID-19","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-07-04","conditions":"COVID","enrollment":3},{"nctId":"NCT04347681","phase":"PHASE2","title":"Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","status":"COMPLETED","sponsor":"King Fahad Specialist Hospital Dammam","startDate":"2020-04-18","conditions":"Convalescent Plasma for COVID 19","enrollment":575},{"nctId":"NCT04353206","phase":"EARLY_PHASE1","title":"Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure","status":"TERMINATED","sponsor":"Noah Merin","startDate":"2020-06-27","conditions":"Covid-19, Sars-CoV2","enrollment":6},{"nctId":"NCT04429854","phase":"PHASE2","title":"Donated Antibodies Working Against nCoV","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-05-02","conditions":"COVID-19","enrollment":483},{"nctId":"NCT04355767","phase":"PHASE3","title":"Convalescent Plasma in Outpatients With COVID-19","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-08-11","conditions":"Covid19","enrollment":511},{"nctId":"NCT04621123","phase":"PHASE2","title":"Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2020-11-10","conditions":"SARS-CoV-2 Infection, Safety and Efficacy","enrollment":384},{"nctId":"NCT04869579","phase":"PHASE2","title":"Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.","status":"UNKNOWN","sponsor":"CHRISTUS Health","startDate":"2021-08-15","conditions":"Covid19","enrollment":100},{"nctId":"NCT04723589","phase":"PHASE2","title":"Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04644198","phase":"PHASE2","title":"Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica","status":"UNKNOWN","sponsor":"The University of The West Indies","startDate":"2021-06-01","conditions":"COVID-19, Convalescent Plasma Treatment","enrollment":30},{"nctId":"NCT04344015","phase":"NA","title":"COVID-19 Plasma Collection","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-04-13","conditions":"COVID-19","enrollment":206},{"nctId":"NCT04542967","phase":"PHASE2","title":"Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease","status":"COMPLETED","sponsor":"Hospital Central Militar","startDate":"2020-06-23","conditions":"Severe COVID-19 Disease","enrollment":150},{"nctId":"NCT04377568","phase":"PHASE2","title":"Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children","status":"WITHDRAWN","sponsor":"The Hospital for Sick Children","startDate":"2020-10-07","conditions":"Hospitalized Children, Covid-19 Infection","enrollment":""},{"nctId":"NCT04836260","phase":"PHASE3","title":"Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2021-04-08","conditions":"Covid19, Immuno-Deficiency, Old Age; Debility","enrollment":100},{"nctId":"NCT04521309","phase":"PHASE1, PHASE2","title":"SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients","status":"COMPLETED","sponsor":"Dow University of Health Sciences","startDate":"2020-06-19","conditions":"COVID-19","enrollment":50},{"nctId":"NCT04547127","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2020-04-29","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04345679","phase":"EARLY_PHASE1","title":"Anti COVID-19 Convalescent Plasma Therapy","status":"UNKNOWN","sponsor":"Orthosera Kft.","startDate":"2020-04-14","conditions":"COVID 19","enrollment":20},{"nctId":"NCT04333355","phase":"PHASE1","title":"Safety in Convalescent Plasma Transfusion to COVID-19","status":"TERMINATED","sponsor":"TecSalud Investigación Clínica","startDate":"2020-05-08","conditions":"COVID-19","enrollment":12},{"nctId":"NCT04547660","phase":"PHASE3","title":"Convalescent Plasma for Severe COVID-19 Patients","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2020-07-16","conditions":"Covid19","enrollment":160},{"nctId":"NCT04712344","phase":"PHASE2","title":"Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2021-01-18","conditions":"Severe COVID-19","enrollment":58},{"nctId":"NCT04550325","phase":"PHASE1, PHASE2","title":"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","status":"COMPLETED","sponsor":"Kamada, Ltd.","startDate":"2020-08-05","conditions":"Covid19, Pneumonia, Viral","enrollment":12},{"nctId":"NCT04634422","phase":"NA","title":"Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure","status":"UNKNOWN","sponsor":"Wladimir Szpirt","startDate":"2020-11-16","conditions":"Respiratory Failure, Renal Failure, Acute","enrollment":220},{"nctId":"NCT04381858","phase":"PHASE3","title":"Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Centenario Hospital Miguel Hidalgo","startDate":"2020-05-06","conditions":"COVID-19 Pneumonia","enrollment":196},{"nctId":"NCT04349410","phase":"PHASE2, PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":"CoVid 19 Positive","enrollment":1800},{"nctId":"NCT04622826","phase":"PHASE2","title":"plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients","status":"UNKNOWN","sponsor":"Azienda USL Toscana Nord Ovest","startDate":"2020-05-15","conditions":"Covid-19 Pneumonia","enrollment":50},{"nctId":"NCT04383535","phase":"NA","title":"Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2020-05-15","conditions":"SARS Virus, SARS-CoV-2, COVID-19","enrollment":333},{"nctId":"NCT04438694","phase":"PHASE1, PHASE2","title":"Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-06-01","conditions":"COVID19","enrollment":67},{"nctId":"NCT04352751","phase":"NA","title":"Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020","status":"UNKNOWN","sponsor":"Hilton Pharma","startDate":"2020-05-01","conditions":"Covid-19","enrollment":2000},{"nctId":"NCT04392414","phase":"PHASE2","title":"Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease","status":"COMPLETED","sponsor":"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","startDate":"2020-05-01","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04388410","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2020-08-25","conditions":"COVID-19","enrollment":410},{"nctId":"NCT04374487","phase":"PHASE2","title":"Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications","status":"UNKNOWN","sponsor":"Max Healthcare Insititute Limited","startDate":"2020-05-09","conditions":"COVID 19","enrollment":100},{"nctId":"NCT04460547","phase":"","title":"Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic","status":"UNKNOWN","sponsor":"Qassim University","startDate":"2020-07-25","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04441424","phase":"NA","title":"Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients","status":"COMPLETED","sponsor":"Alkarkh Health Directorate-Baghdad","startDate":"2020-04-03","conditions":"IMMUNOTHERAPY","enrollment":49},{"nctId":"NCT04442191","phase":"PHASE2","title":"Convalescent Plasma as a Possible Treatment for COVID-19","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2020-05-05","conditions":"COVID-19","enrollment":50},{"nctId":"NCT04346446","phase":"PHASE2","title":"Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2020-04-20","conditions":"COVID","enrollment":29},{"nctId":"NCT04425837","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19","status":"UNKNOWN","sponsor":"Fundación Santa Fe de Bogota","startDate":"2020-07","conditions":"Sars-CoV2, Covid-19","enrollment":236},{"nctId":"NCT04403477","phase":"PHASE2","title":"Convalescent Plasma Therapy in Severe COVID-19 Infection","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2020-05-20","conditions":"Covid19, Convalescence","enrollment":20},{"nctId":"NCT04292340","phase":"","title":"Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2020-02-01","conditions":"Coronavirus","enrollment":15},{"nctId":"NCT02333578","phase":"NA","title":"Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment","status":"UNKNOWN","sponsor":"Clinical Research Management, Inc.","startDate":"2014-11","conditions":"Ebola Virus Disease","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"COVID19 convalescent plasma infusion","genericName":"COVID19 convalescent plasma infusion","companyName":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","companyId":"centro-de-educaci-n-medica-e-investigaciones-cl-nicas-norberto-quirno","modality":"Biologic","firstApprovalDate":"","aiSummary":"COVID-19 convalescent plasma infusion transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against SARS-CoV-2. Used for COVID-19 (severe or life-threatening disease), COVID-19 (hospitalized patients).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}